Intuitive Surgical is the global leader in robotic-assisted surgery and the creator of the da Vinci surgical system. The company enables surgeons to perform minimally invasive procedures with greater precision while generating revenue through a broad ecosystem of robots, instruments, software, and services. Intuitive delivered another strong quarter, driven by growing adoption of robotic surgery worldwide. Revenue increased 22% year-over-year to $3.05 billion, while its installed base expanded to more than 13,000 systems globally. Procedure growth remained healthy across both developed and emerging markets, demonstrating the continued shift toward robotic-assisted surgery. A key investment attraction is Intuitive’s razor-and-blades business model. While the company earns revenue from selling da Vinci systems, the real value comes after installation. Every surgical procedure requires Intuitive’s proprietary instruments and accessories, many of which have limited usage lives and need regular replacement. Hospitals also pay for service and maintenance contracts. As a result, the company benefits every time a surgeon performs a procedure, creating a highly recurring revenue stream. This was evident in the quarter, with instruments and accessories generating significantly more revenue than system sales. One notable item during the quarter was a $450 million litigation charge. The charge relates to a proposed settlement of a long-running U.S. hospital antitrust lawsuit concerning third-party servicing and repair of da Vinci systems. Under the settlement, third-party providers may service Intuitive Surgical’s machines, provided they meet the company’s standards. Importantly, the settlement does not represent an admission of wrongdoing. Instead, it aims to resolve the dispute and remove a legal overhang that has weighed on the company for years. Looking ahead, Intuitive has several growth opportunities. These include increasing adoption of robotic surgery internationally, expanding into ambulatory surgery centres, growing the recently launched da Vinci 5 platform, and scaling its ION lung biopsy system. The company also continues to penetrate high-volume benign procedures, which could significantly expand procedure volumes over time. Risks remain. Pricing initiatives may reduce revenue per procedure, competitors are investing heavily in robotic surgery, and hospitals may delay capital spending during periods of economic uncertainty. Nevertheless, Intuitive’s dominant market position and recurring revenue model leave it well placed to benefit from the growing adoption of robotic-assisted surgery. | 
